ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022

Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine.

Casey L O'Connell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.